CAMBRIDGE, Mass. & SALISBURY, England - KalVista Pharmaceuticals, Inc. (NASDAQ: NASDAQ:KALV) has received Orphan Drug ...
KalVista (KALV) announced that Japan’s Ministry of Health, Labour and Welfare, or MHLW, has granted sebetralstat orphan drug designation. The ...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has ...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced that the compensation committee of KalVista’s board of ...
“I am confident that his proven skills will help us to achieve our goal of delivering sebetralstat to help transform the lives of people living with hereditary angioedema.” “I am excited to ...
KalVista Pharmaceuticals Inc. submitted a new drug application to the FDA for the approval of sebetralstat for patients aged 12 years and older with hereditary angioedema (HAE). Sebetralstat is ...
Hosted on MSN1mon
KalVista wins new Buy at BofA on potential of lead candidateBank of America on Wednesday launched its coverage of KalVista Pharmaceuticals (NASDAQ:KALV) with a Buy recommendation, citing a broad uptake for the company’s lead candidate, sebetralstat.
Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P.
KalVista Pharmaceuticals, Inc. (KALV) announced Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback